Carlos Brites
Carlos Brites is an expert in Infectiology at Complexo Hospitalar Universitário Professor Edgard Santos (Brazil). As of October 2026, ScienceLeadR ranks Carlos Brites in the top 1% of experts worldwide for HIV Infections and Immunologic Deficiency Syndromes. Carlos Brites has authored 328 publications, the most recent in 2026, and is an investigator in 17 clinical trials, 6 of them ongoing. SLR score: 1,291 (community average: 125). How the SLR is computed.
LeadR Profile
Infectiology
Subspecialties: Public Health - Immunology - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 1992 - 2026
Number : 328
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 17
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
6 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Dolutegravir Lamivudine in Treatment Na ve Pregnant Women NCT07616739 — pregnant women, hiv-1, pregnancy, safety, incidence, lamivudine, tablets, hiv, emtricitabine, therapeutics, infections, dolutegravir, women | Phase 4 | Not yet recruiting | 2026 |
| Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV 1 Infection NCT07555431 — cells, tenofovir, leukemia-lymphoma, adult t-cell, human t-lymphotropic virus 1, lymphoma, neuritis, leukemia, leukemia, t-cell, paraparesis, tropical spastic, therapeutics, htlv-i infections, t-lymphocytes, spinal cord diseases, infections, paraparesis, dolutegravir | Phase 2 | Recruiting | 2026 |
| Dolutegravir Lamivudine Dual Therapy for ART na ve People With HIV and TB Receiving Rifampin based TB Treatment NCT06497465 — tenofovir, lamivudine, tablets, fumarates, tuberculosis, therapeutics, rifampin, dolutegravir | Phase 3 | Recruiting | 2025 |
| A Study of Propranolol to Treat Kaposi Sarcoma NCT05797662 — sarcoma, kaposi, propranolol, suspensions, tablets, sarcoma, therapeutics, mouth, child | Phase 2 | Recruiting | 2026 |
| Pre Exposure Prophylaxis Study of Lenacapavir in Cisgender Men Transgender Women Transgender Men and Gender Nonbinary People at Risk for HIV Infection NCT04925752 — injections, emtricitabine, tenofovir disoproxil fumarate drug combination, tenofovir, safety, parturition, pre-exposure prophylaxis, pharmaceutical preparations, drug combinations, tablets, food, fumarates, emtricitabine, sex, hiv infections, infections, male, women | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map